MedTrace Logo

Vaporized Cannabis and Spinal Cord Injury Pain

NCT01555983 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-04-18

Study results available
· View outcomes & findings →

Summary

This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will also be measured.

Conditions

  • Spinal Cord Injuries
  • Spinal Cord Diseases

Interventions

DRUG

Vaporization of Cannabis

Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC

Sponsors & Collaborators

  • VA Northern California Health Care System

    collaborator FED

  • University of California, San Diego

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Barth Wilsey

    lead OTHER

Principal Investigators

  • Barth Wilsey, MD · UC San Diego, Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01555983 on ClinicalTrials.gov